Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2016 / Aug / Business in Brief
Professional Development

Business in Brief

It’s been a busy summer in the ophthalmic business space…

By Ruth Steer 8/9/2016 1 min read

Share

  • Carl Zeiss Meditec AG made two big announcements. One, they’ve consolidated their ophthalmology activities into a single strategic business unit, and two, they’ve recruited Jim Mazzo to lead it. As the Global President of Ophthalmology, Mazzo will oversee both the new unit and CZM’s US Sales and Service Center.
  • Mazzo joined CZM from AcuFocus, who were quick to announce his replacements: Andrew Waterhouse as president and COO, and William Link as Chairman of the Board.
  • A deal – potentially worth up to $800 million – has been struck to allow Santen to acquire InnFocus, the manufacturer of the MIGS MicroShunt device.
  • The second MIGS device is now available for the US market with the FDA approval of Alcon’s CyPass MicroStent System.
  • The FDA has approved Shire’s lifitegrast ophthalmic solution 5%, twice-daily drops for the treatment of the signs and symptoms of dry eye in adults, the Raindrop Near Vision inlay, plus AMO’s Tecnis Symfony IOL (and four toric variants of the IOL).
  • Pixium Vision’s epiretinal implant – the IRIS II bionic vision system – receives CE mark certification, and its long-term performance continues to be evaluated in several centers across Europe.
  • Twenty-four month follow-up data from the Phase IIIb OASIS clinical trial that evaluated the efficacy and safety of ocriplasmin in patients with symptomatic vitreomacular adhesions have now been published. The study authors concluded that “the OASIS trial demonstrates the long-term efficacy and safety of ocriplasmin, providing improved resolution of symptomatic VMA compared with previous phase III trials with no additional safety signals identified.”
  • Clearside Biomedical announced additional results from their Phase II TANZANITE trial (NCT02303184). Patients (n=46) with macular edema and retinal vein occlusion were randomized to receive either Zuprata (Clearside’s proprietary triamcinolone acetonide formulation) and aflibercept, and aflibercept alone. Over a three month period, 78 percent of patients who received dual therapy required no additional treatment, whereas 30 percent of patients in the aflibercept-only arm did (p=0.003). Clearside hope to commence a Phase III clinical program in early 2017.

About the Author(s)

Ruth Steer

More Articles by Ruth Steer

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: